Clinical trial
Cetuximab in Treating Patients With Advanced Solid Tumors
NCT00376727 · University of California, Davis, Other · Completed
Key facts
| NCT number | NCT00376727 |
|---|---|
| Title | Cetuximab in Treating Patients With Advanced Solid Tumors |
| Official title | A Phase I Study of the Safety and Tolerability of Four Doses of Cetuximab (C225) in Patients With Advanced Solid Tumors |
| Lead sponsor | University of California, Davis, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological, Genetic, Other |
| Interventions | cetuximab, molecular diagnostic method, immunologic technique, laboratory biomarker analysis |
| Enrollment | 27 |
| Start date | Dec 1, 2004 |
| Primary completion | Nov 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Sep 15, 2006 |
| Last update posted | Mar 29, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: